ESMO Guidelines on HRD Testing
in Ovarian Cancer Exam Questions
and Answers
Average number of women diagnosed with HGSC annually - Answer-Almost 250,000
women worldwide.
HRR - Answer-Homologous recombination repair; DNA damage restoration.
S and G2 phases - Answer-Cell cycle phases where HRR predominantly occurs.
DSB - Answer-Double-strand break; critical DNA damage type.
Resection - Answer-Removal of DNA sequence around DSB.
ssDNA - Answer-Single-stranded DNA exposed during resection.
RAD51 - Answer-DNA recombinase that binds ssDNA for repair.
BRCA1 - Answer-Gene crucial for HRR; mutations lead to HRD.
BRCA2 - Answer-Gene involved in DNA repair; linked to HRD.
HRD - Answer-Homologous recombination deficiency; impaired DNA repair.
BRCAness - Answer-Cancers resembling BRCA-mutant phenotypes.
PARP inhibitors - Answer-Drugs targeting PARP proteins; exploit HRD vulnerabilities.
HRP - Answer-Homologous recombination proficiency; effective DNA repair.
Topoisomerase inhibitors - Answer-Drugs affecting DNA topology; used in cancer
therapy.
Platinum salts - Answer-Chemotherapy agents; effective against HRD cancers.
HGSC - Answer-High-grade serous carcinoma; associated with HRD.
Synthetic lethality - Answer-Cell death from combined genetic defects.
Clinical Validity - Answer-Accuracy of predicting PARP inhibitor benefit.
in Ovarian Cancer Exam Questions
and Answers
Average number of women diagnosed with HGSC annually - Answer-Almost 250,000
women worldwide.
HRR - Answer-Homologous recombination repair; DNA damage restoration.
S and G2 phases - Answer-Cell cycle phases where HRR predominantly occurs.
DSB - Answer-Double-strand break; critical DNA damage type.
Resection - Answer-Removal of DNA sequence around DSB.
ssDNA - Answer-Single-stranded DNA exposed during resection.
RAD51 - Answer-DNA recombinase that binds ssDNA for repair.
BRCA1 - Answer-Gene crucial for HRR; mutations lead to HRD.
BRCA2 - Answer-Gene involved in DNA repair; linked to HRD.
HRD - Answer-Homologous recombination deficiency; impaired DNA repair.
BRCAness - Answer-Cancers resembling BRCA-mutant phenotypes.
PARP inhibitors - Answer-Drugs targeting PARP proteins; exploit HRD vulnerabilities.
HRP - Answer-Homologous recombination proficiency; effective DNA repair.
Topoisomerase inhibitors - Answer-Drugs affecting DNA topology; used in cancer
therapy.
Platinum salts - Answer-Chemotherapy agents; effective against HRD cancers.
HGSC - Answer-High-grade serous carcinoma; associated with HRD.
Synthetic lethality - Answer-Cell death from combined genetic defects.
Clinical Validity - Answer-Accuracy of predicting PARP inhibitor benefit.
